Jacques Bonneterre

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Belkacémi Yazid; Chauvet Marie-Pierre; Giard Sylvia; Villette Sylviane; Lacornerie Thomas; Bonodeau François; Baranzelli Marie-Christine; Bonneterre Jacques; Lartigau Eric
Partial breast irradiation as sole therapy for low risk breast carcinoma: early toxicity, cosmesis and quality of life results of a MammoSite brachytherapy phase II study.
Bonneterre Jacques; Penel Nicolas
Vinorelbine in breast cancer.
Burzykowski Tomasz; Buyse Marc; Piccart-Gebhart Martine J; Sledge George; Carmichael James; Lück Hans-Joachim; Mackey John R; Nabholtz Jean-Marc; Paridaens Robert; Biganzoli Laura; Jassem Jacek; Bontenbal Marijke; Bonneterre Jacques; Chan Stephen; Basaran Gul Atalay; Therasse Patrick
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jacques Bonneterre (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Belkacémi Yazid; Chauvet Marie-Pierre; Giard Sylvia; Villette Sylviane; Lacornerie Thomas; Bonodeau François; Baranzelli Marie-Christine; Bonneterre Jacques; Lartigau Eric
Partial breast irradiation as sole therapy for low risk breast carcinoma: early toxicity, cosmesis and quality of life results of a MammoSite brachytherapy phase II study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2009;90(1):23-9.
2008: Bonneterre Jacques; Penel Nicolas
Vinorelbine in breast cancer.
Expert opinion on pharmacotherapy 2008;9(16):2901-10.
2008: Burzykowski Tomasz; Buyse Marc; Piccart-Gebhart Martine J; Sledge George; Carmichael James; Lück Hans-Joachim; Mackey John R; Nabholtz Jean-Marc; Paridaens Robert; Biganzoli Laura; Jassem Jacek; Bontenbal Marijke; Bonneterre Jacques; Chan Stephen; Basaran Gul Atalay; Therasse Patrick
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1987-92.
2008: Piccart-Gebhart Martine J; Burzykowski Tomasz; Buyse Marc; Sledge George; Carmichael James; Lück Hans-Joachim; Mackey John R; Nabholtz Jean-Marc; Paridaens Robert; Biganzoli Laura; Jassem Jacek; Bontenbal Marijke; Bonneterre Jacques; Chan Stephen; Basaran Gul Atalay; Therasse Patrick
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1980-6.
2008: Penel Nicolas; Saleron Julia; Lansiaux Amélie; Clisant Stéphanie; Adenis Antoine; Fournier Charles; Duhamel Alain; Bonneterre Jacques
[Methodological approaches of clinical studies with targeted therapies]
Bulletin du cancer 2008;95(2):185-90.
2008: Penel Nicolas; Vanseymortier Marie; Bonneterre Marie-Edith; Clisant Stéphanie; Dansin Eric; Vendel Yvette; Beuscart Régis; Bonneterre Jacques
Prognostic factors among cancer patients with good performance status screened for phase I trials.
Investigational new drugs 2008;26(1):53-8.
2008: Révillion F; Lhotellier V; Hornez L; Leroy A; Baranzelli M C; Giard S; Bonneterre J; Peyrat J-P
Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion.
The International journal of biological markers 2008;23(1):10-7.
2008: Vieillard Marie-Hélène; Maes Jean-Michel; Penel Guillaume; Facon Thierry; Magro Leonardo; Bonneterre Jacques; Cortet Bernard
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
Joint, bone, spine : revue du rhumatisme 2008;75(1):34-40.
2008: Révillion F; Lhotellier V; Hornez L; Bonneterre J; Peyrat J-P
ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(1):73-80.
2007: Bonneterre J; Campone M; Koralewski P; Blasinska-Morawiec M; Deporte-Fety R; Chatelut E; Leger F; Longerey B; Ecochard L; Douville I
Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study.
Cancer chemotherapy and pharmacology 2007;60(3):365-73.
2007: Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier M-J; Audhuy B; Simon H; Montcuquet P; Eymard J-C; Walter S; Clavère P; Guastalla J-P;
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
British journal of cancer 2007;96(11):1633-8.
2006: Roché Henri; Fumoleau Pierre; Spielmann Marc; Canon Jean-Luc; Delozier Thierry; Serin Daniel; Symann Michel; Kerbrat Pierre; Soulié Patrick; Eichler Françoise; Viens Patrice; Monnier Alain; Vindevoghel Anita; Campone Mario; Goudier Marie-Josèphe; Bonneterre Jacques; Ferrero Jean-Marc; Martin Anne-Laure; Genève Jean; Asselain Bernard
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(36):5664-71.
2006: Héry Michel; Bonneterre Jacques; Roché Henri; Luporsi Elisabeth; Kerbrat Pierre; Namer Moïse; Fumoleau Pierre; Monnier Alain; Fargeot Pierre
Epirubicin-based chemotherapy as adjuvant treatment for poor prognosis, node-negative breast cancer: 10-year follow-up results of the French Adjuvant Study Group 03 trial.
Bulletin du cancer 2006;93(10):E109-14.
2006: Roché H; Kerbrat P; Bonneterre J; Fargeot P; Fumoleau P; Monnier A; Clavère P; Goudier M-J; Chollet P; Guastalla J-P; Serin D
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(8):1221-7.
2006: Kuppens Isa E L M; Dansin Eric; Boot Henk; Feger Celine; Assadourian Sylvia; Bonneterre Maria-Edith; Beijnen Jos H; Schellens Jan H M; Bonneterre Jacques
Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(12):3774-81.
2006: Bonneterre M E; Bonneterre J
Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(5):875; reply 875-6.
2006: Desauw Christophe; Bonneterre Jacques
[Antineoplastic treatment and venous thrombosis]
Bulletin du cancer 2006;93(2):171-8.
2006: Namer M; Fargeot P; Roché H; Campone M; Kerbrat P; Romestaing P; Monnier A; Luporsi E; Montcuquet P; Bonneterre J;
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(1):65-73.
2006: Fumoleau P; Roché H; Kerbrat P; Bonneterre J; Romestaing P; Fargeot P; Namer M; Monnier A; Montcuquet P; Goudier M-J; Luporsi E;
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(1):85-92.
2005: Baranzelli Marie-Christine; Giard Sylvia; Cabaret Véronique; Chauvet Marie-Pierre; Robin Yves-Marie; Vilain Marie-Odile; Carpentier Philippe; Belkacémi Yazid; Bonneterre Jacques
[Breast adenocarcinoma: critical analysis of sentinel lymph node histopathological results of 542 procedures]
Bulletin du cancer 2005;92(11):983-7.
2005: Diéras Véronique; Bonneterre Jacques; Laurence Valérie; Degardin Marian; Pierga Jean-Yves; Bonneterre Marie-Edith; Marreaud Sandrine; Lacombe Denis; Fumoleau Pierre
Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6256-60.
2005: Campone M; Roché H; Kerbrat P; Bonneterre J; Romestaing P; Fargeot P; Namer M; Monnier A; Montcuquet P; Goudier M-J; Fumoleau P
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1343-51.
2005: Vanhuyse M; Fournier C; Bonneterre J
Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1283-8.
2005: Praga Claudio; Bergh Jonas; Bliss Judith; Bonneterre Jacques; Cesana Bruno; Coombes R Charles; Fargeot Pierre; Folin Annika; Fumoleau Pierre; Giuliani Rosa; Kerbrat Pierre; Hery Michel; Nilsson Jonas; Onida Francesco; Piccart Martine; Shepherd Lois; Therasse Patrick; Wils Jacques; Rogers David
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4179-91.
2005: Bonneterre J; Bercez C; Bonneterre M-E; Lenne X; Dervaux B
Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(6):915-22.
2005: Giard S; Chauvet M-P; Houpeau J-L; Baranzelli M-C; Carpentier P; Fournier C; Belkacemi Y; Bonneterre J
[Sentinel node biopsy without systematic axillary dissection: study about 1000 procedures]
Gynécologie, obstétrique & fertilité 2005;33(4):213-9.
2005: Bonneterre Jacques; Roché Henri; Kerbrat Pierre; Brémond Alain; Fumoleau Pierre; Namer Moïse; Goudier Marie-Josèphe; Schraub Simon; Fargeot Pierre; Chapelle-Marcillac Isabelle
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2686-93.
2005: Arriagada R; Lê M G; Spielmann M; Mauriac L; Bonneterre J; Namer M; Delozier T; Hill C; Tursz T
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(3):389-96.
2004: Fargeot Pierre; Bonneterre Jacques; Roché Henri; Lortholary Alain; Campone Mario; Van Praagh Isabelle; Monnier Alain; Namer Moïse; Schraub Simon; Barats Jean-Claude; Guastalla Jean-Paul; Goudier Marie-Josèphe; Chapelle-Marcillac Isabelle
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4622-30.
2004: Conroy T; Mercier M; Bonneterre J; Luporsi E; Lefebvre J L; Lapeyre M; Puyraveau M; Schraub S
French version of FACT-G: validation and comparison with other cancer-specific instruments.
European journal of cancer (Oxford, England : 1990) 2004;40(15):2243-52.
2004: Bonneterre J; Dieras V; Tubiana-Hulin M; Bougnoux P; Bonneterre M-E; Delozier T; Mayer F; Culine S; Dohoulou N; Bendahmane B
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer.
British journal of cancer 2004;91(8):1466-71.
2004: Bonneterre Jacques; Roché Henri; Kerbrat Pierre; Fumoleau Pierre; Goudier Marie-Josèphe; Fargeot Pierre; Montcuquet Philippe; Clavère Pierre; Barats Jean-Claude; Monnier Alain; Veyret Corinne; Datchary Jean; Van Praagh Isabelle; Chapelle-Marcillac Isabelle
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3070-9.
2004: Avril M F; Aamdal S; Grob J J; Hauschild A; Mohr P; Bonerandi J J; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba J L; Scherrer A; Menu Y
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(6):1118-25.
2004: Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S
Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
Cancer chemotherapy and pharmacology 2004;53(3):233-8.
2004: Bonneterre Jacques; Tubiana-Hulin Michèle; Catimel Gilles
Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
Oncology 2004;66(3):185-91.
2003: Thürlimann B; Robertson J F R; Nabholtz J M; Buzdar A; Bonneterre J;
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.
European journal of cancer (Oxford, England : 1990) 2003;39(16):2310-7.
2003: Nabholtz J M; Bonneterre J; Buzdar A; Robertson J F R; Thürlimann B
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
European journal of cancer (Oxford, England : 1990) 2003;39(12):1684-9.
2003: Urien S; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Deporte-Fety R
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Cancer chemotherapy and pharmacology 2003;52(2):99-107.
2003: Hebbar M; Krzewinski-Recchi M A; Hornez L; Verdière A; Harduin-Lepers A; Bonneterre J; Delannoy P; Peyrat J P
Prognostic value of tumoral sialyltransferase expression and circulating E-selectin concentrations in node-negative breast cancer patients.
The International journal of biological markers 2003;18(2):116-22.
2003: Fumoleau Pierre; Bonneterre Jacques; Luporsi Elisabeth
Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1190-1; author reply 1191-2.
2003: Mornex F; Thomas L; Mohr P; Hauschild A; Delaunay M M; Lesimple T; Tilgen W; Nguyen B B; Guillot B; Ulrich J; Bourdin S; Mousseau M; Cupissol D; Bonneterre J; de Gislain C; Bensadoun J R; Clavel M
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique 2003;7(1):1-8.
2002: Bonneterre J; Roché H; Monnier A; Guastalla J P; Namer M; Fargeot P; Assadourian S
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
British journal of cancer 2002;87(11):1210-5.
2002: Héry Michel; Delozier Thierry; Ramaioli Alain; Julien Jean-Pierre; de Lafontan Brigitte; Petit Thierry; de Ghislain Catherine; Weber Béatrice; Bonneterre Jacques; Teissier Eric
Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?
Breast (Edinburgh, Scotland) 2002;11(5):442-8.
2001: Bonneterre J; Chevalier B; Focan C; Mauriac L; Piccart M
Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(12):1683-91.
2001: Bonneterre J; Buzdar A; Nabholtz J M; Robertson J F; Thürlimann B; von Euler M; Sahmoud T; Webster A; Steinberg M;
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Cancer 2001;92(9):2247-58.
2001: Fumoleau P; Chauvin F; Namer M; Bugat R; Tubiana-Hulin M; Guastalla J P; Delozier T; Kerbrat P; Devaux Y; Bonneterre J; Filleul A; Clavel M
Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):612-20.
2000: Bonneterre J; Thürlimann B; Robertson J F; Krzakowski M; Mauriac L; Koralewski P; Vergote I; Webster A; Steinberg M; von Euler M
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(22):3748-57.
2000: Fumoleau P; Déporte R; Kerbrat P; Bonneterre J; Fargeot P
UFT/leucovorin plus vinorelbine combination for advanced breast cancer.
Oncology (Williston Park, N.Y.) 2000;14(10 Suppl 9):50-5.
2000: Vergote I; Bonneterre J; Thürlimann B; Robertson J; Krzakowski M; Mauriac L; Koralewski L; Webster A; Steinberg M; von Euler M
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
European journal of cancer (Oxford, England : 1990) 2000;36 Suppl 4():S84-5.
2000: Rougier P; Adenis A; Ducreux M; de Forni M; Bonneterre J; Dembak M; Clouet P; Lebecq A; Baille P; Lefresne-Soulas F; Blanc C; Armand J P
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.
European journal of cancer (Oxford, England : 1990) 2000;36(8):1016-25.
2000: Kvinnsland S; Anker G; Dirix L Y; Bonneterre J; Prove A M; Wilking N; Lobelle J P; Mariani O; di Salle E; Polli A; Massimini G
High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.
European journal of cancer (Oxford, England : 1990) 2000;36(8):976-82.
2000: Alexandre J; Bleuzen P; Bonneterre J; Sutherland W; Misset J L; Guastalla J; Viens P; Faivre S; Chahine A; Spielman M; Bensmaïne A; Marty M; Mahjoubi M; Cvitkovic E
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):562-73.
1999: Bonneterre J; Spielman M; Guastalla J P; Marty M; Viens P; Chollet P; Roché H; Fumoleau P; Mauriac L; Bourgeois H; Namer M; Bergerat J P; Misset J L; Trandafir L; Mahjoubi M
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.
European journal of cancer (Oxford, England : 1990) 1999;35(10):1431-9.
1999: Bercez C; Lebrun T; Bonneterre M E; Selke B; Lenne X; Bonneterre J
[Advanced breast cancer: an evaluation of the cost of recurrence]
Bulletin du cancer 1999;86(6):585-90.
1999: Hebbar M; Révillion F; Louchez M M; Fournier C; Bonneterre J; Peyrat J P
Prognostic value of circulating soluble E-selectin concentrations in node-negative breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1427-33.
1998: Selke B; Bercez C; Lenne X; Bonneterre M E; Lebrun T; Bonneterre J
[Adjuvant treatment of cancer of the breast: cost assessment of the protocol used]
Bulletin du cancer 1998;85(11):961-6.
1998: Huc P; Block S; Carlier D; Darloy F; Bonneterre M E; Bleuse J P; Fournier C; Bonneterre J
[Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord]
Bulletin du cancer 1998;85(6):562-8.
1998: Révillion F; Bonneterre J; Peyrat J P
ERBB2 oncogene in human breast cancer and its clinical significance.
European journal of cancer (Oxford, England : 1990) 1998;34(6):791-808.
1998: Vanlemmens L; Hebbar M; Peyrat J P; Bonneterre J
Age as a prognostic factor in breast cancer.
Anticancer research 1998;18(3B):1891-6.
1998: Peyrat J P; Révillion F; Bonneterre J
Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.
British journal of cancer 1998;77(10):1669-71.
1998: Peyrat J P; Vennin P; Hornez L; Fournier J; Adenis C; Bonneterre J
Germline BRCA1 mutations in patients from 84 families with breast and/or ovarian cancers in northern France.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 1998;7 Suppl 1():S7-12.
1998: Mercier M; Bonneterre J; Schraub S; Lecomte S; el Hasnaoui A
The development of a French version of a questionnaire on the quality of life in cancerology (Functional Living Index-Cancer: FLIC).
Bulletin du cancer 1998;85(2):180-6.
1998: Hebbar M; Révillion F; Louchez M M; Vilain M O; Fournier C; Bonneterre J; Peyrat J P
The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):373-80.
1998: Peyrat J P; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):189-96.
1997: Thürlimann B; Paridaens R; Serin D; Bonneterre J; Roché H; Murray R; di Salle E; Lanzalone S; Zurlo M G; Piscitelli G
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group.
European journal of cancer (Oxford, England : 1990) 1997;33(11):1767-73.
1997: Leriche N; Bonneterre J
[Progestational agents and bone metastasis in breast cancer]
Bulletin du cancer 1997;84(9):891-4.
1997: Lebrun T; Selke B; Bercez C; Bonneterre M E; Lenne X; Sailly J C; Bonneterre J
[Medico-economical assessment in cancerology]
Bulletin du cancer 1997;84(5):543-6.
1997: Vilain M O; Delobelle-Deroide A; Bloget F; Cabaret V; Peyrat J P; Fournier C; Hecquet B; Fournier J; Vennin P; Bonneterre J
[Immunohistochemical detection of estradiol and progesterone receptors in paraffin sections after treatment with microwaves. Comparison with biochemical assay of receptors in a series of 123 breast cancers with determination of the threshold of optimal positivity]
Annales de pathologie 1997;17(2):82-8.
1997: Lemenager M; Lecomte S; Bonneterre M E; Bessa E; Dauba J; Bonneterre J
Effectiveness of cold cap in the prevention of docetaxel-induced alopecia.
European journal of cancer (Oxford, England : 1990) 1997;33(2):297-300.
1997: Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla J P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Seminars in oncology 1997;24(1 Suppl 3):S8-12.
1997: Peyrat J P; Vennin P; Hornez L; Bonneterre J
[Germ-line mutation of BRCA1 in patients with breast and/or ovarian cancer in high risk families in Northern France]
Bulletin du cancer 1997;84(1):41-6.
1997: Rougier P; Bugat R; Douillard J Y; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra J M; Bonneterre J; Adenis A; Seitz J F; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):251-60.
1996: Adenis A; Leriche N; Pion J M; Vanlemmens L; Bonneterre J
Ineffectiveness of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX regimen) as a salvage therapy in advanced colorectal cancers and other gastrointestinal tumors.
Anticancer research 1996;16(4A):2063-7.
1996: Soussi T; Peyrat J P; Lubin R; Bonneterre J
[P53 antibodies: a new method for the analysis of alterations of the p53 gene: application to breast cancer]
Pathologie-biologie 1996;44(4):232-4.
1996: Revillion F; Hebbar M; Bonneterre J; Peyrat J P
Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients.
European journal of cancer (Oxford, England : 1990) 1996;32A(2):231-4.
1996: Bonneterre J; Schraub S; Lecomte S; Mercier M
Quality of life as an outcome in breast cancer. Clinical application.
PharmacoEconomics 1996;9 Suppl 2():23-9.
1996: Adenis A; Vanlemmens L; Fournier C; Hecquet B; Bonneterre J
Does induction chemotherapy with a mitoxantrone/vinorelbine regimen allow a breast-conservative treatment in patients with operable locoregional breast cancer? A French Northern Oncology Group trial in 105 patients. French Northern Oncology Group.
Breast cancer research and treatment 1996;40(2):161-9.
1995: Bonneterre J
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan]
Bulletin du cancer 1995;82(8):623-8.
1995: Nguyen-Pamart M; Bonneterre J; Hecquet B
Urinary excretion of deoxypyridinoline in patients with breast cancer.
Anticancer research 1995;15(4):1601-3.
1995: Adenis A; Carlier D; Darloy F; Pion J M; Bonneterre J; Demaille A
Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-fluorouracil + folinic acid regimen. French Northern Oncology Group.
American journal of clinical oncology 1995;18(2):158-60.
1995: Decouvelaere C; Peyrat J P; Bonneterre J; Djiane J; Jammes H
Presence of the two growth hormone receptor messenger RNA isoforms in human breast cancer.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1995;6(4):477-83.
1995: Peyrat J P; Bonneterre J; Lubin R; Vanlemmens L; Fournier J; Soussi T
Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer.
Lancet 1995;345(8950):621-2.
1995: Hebbar M; Hecquet B; Vanlemmens L; Lecomte S; Pion J M; Adenis A; Bonneterre J
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy]
Bulletin du cancer 1995;82(1):67-9.
1995: Hebbar M; Bonneterre J; Fournier C; Vanlemmens L; Pion J M; Adenis A; Kamus E; Hecquet B; Conroy T; Tubiana-Hulin M
Randomized trial comparing conventional intravenous bolus FEC and FEC with high-dose infusional 5-fluorouracil as first-line treatment of advanced breast cancer.
The Journal of infusional chemotherapy 1995;5(4):201-5.
1995: Adenis A; Pion J M; Fumoleau P; Pouillart P; Marty M; Giroux B; Bonneterre J
Phase II study of a new vinca alkaloid derivative, S12363, in advanced breast cancer.
Cancer chemotherapy and pharmacology 1995;35(6):527-8.
1995: Hebbar M; Vanlemmens L; Lecomte S; Bonneterre J
[Immunotherapy of malignant melanoma. New prospects]
La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne 1995;16(4):260-70.
1995: Adenis A; Peyrat J P; Hecquet B; Delobelle A; Depadt G; Quandalle P; Bonneterre J; Demaille A
Type I insulin-like growth factor receptors in human colorectal cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(1):50-5.
1995: Schraub S; Lecomte S; Mercier M; Bonneterre J; Arveux P
[Quality of life measures in oncology]
Bulletin du cancer. Radiothérapie : journal de la Société française du cancer : organe de la société française de radiothérapie oncologique 1995;82(2):79-84.
1994: Bonneterre J
Is ondansetron cost effective?
PharmacoEconomics 1994;6(6):581-3.
1994: Degardin M; Bonneterre J; Hecquet B; Pion J M; Adenis A; Horner D; Demaille A
Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(5):423-6.
1994: Chevalier-Evain V; Bonneterre J; Adenis A; Pion J M; Hecquet B
Loss of efficacy of ondansetron-dexamethasone during successive courses in female patients receiving high-dose cisplatin.
Bulletin du cancer 1994;81(3):219-22.
1994: Lecomte S; Adenis A; Bonneterre J
[Antiemetic treatment and chemotherapy: general review]
La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne 1994;15(11):752-69.
1993: Bonneterre J; Mercier M
Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group.
Cancer treatment reviews 1993;19 Suppl B():21-30.
1993: Bonneterre J; Adenis A; Pion J M; Cambier L; Kamus E; Hecquet B
Aminoglutethimide (AG) and hydrocortisone (HC) in bone metastases: a retrospective study.
The Journal of steroid biochemistry and molecular biology 1993;44(4-6):693-6.
1993: Adenis A; Bonneterre J; Pion J M; Degardin M; Horner D
Unexpected fatal toxicity related to low-dose leucovorin with 5-fluorouracil treatment in metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(2):174-5.
1993: Vennin P; Peyrat J P; Bonneterre J; Depadt G; Laurent J C; Deligny N
[Surgery of breast cancer and date of last menstruation]
Bulletin du cancer 1993;80(2):111-2.
1993: Peyrat J P; Bonneterre J; Hecquet B; Vennin P; Louchez M M; Fournier C; Lefebvre J; Demaille A
Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer.
European journal of cancer (Oxford, England : 1990) 1993;29A(4):492-7.
1993: Preudhomme C; Fenaux P; Peyrat J P; Fournier J; Bonneterre J; Vennin P
Absence of germline mutations of exons 5 to 8 of the P53 gene in 26 breast cancer families from the north of France.
European journal of cancer (Oxford, England : 1990) 1993;29A(10):1476-8.
1992: Peyrat J P; Bonneterre J; Hondermarck H; Hecquet B; Adenis A; Louchez M M; Lefebvre J; Boilly B; Demaille A
Basic fibroblast growth factor (bFGF): mitogenic activity and binding sites in human breast cancer.
The Journal of steroid biochemistry and molecular biology 1992;43(1-3):87-94.
1992: Jammes H; Peyrat J P; Ban E; Vilain M O; Haour F; Djiane J; Bonneterre J
Insulin-like growth factor 1 receptors in human breast tumour: localisation and quantification by histo-autoradiographic analysis.
British journal of cancer 1992;66(2):248-53.
1992: Block S; Bonneterre J; Adenis A; Pion J M; Demaille A
Aminoglutethimide in malignant melanoma. A phase II study.
American journal of clinical oncology 1992;15(3):260-1.
1992: Bonneterre J
[Meta-analysis of adjuvant medical treatment in breast cancers. Ten year results]
Bulletin du cancer 1992;79(5):459-64.
1992: Peyrat J P; Bonneterre J
Type 1 IGF receptor in human breast diseases.
Breast cancer research and treatment 1992;22(1):59-67.
1992: Peyrat J P; Hondermarck H; Hecquet B; Adenis A; Bonneterre J
[FGFB binding sites in cancers of the human breast]
Bulletin du cancer 1992;79(3):251-60.
1992: Degardin M; Hecquet B; Bonneterre J; Adenis A; Pion J M; Demaille A
[A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers]
Bulletin du cancer 1992;79(2):169-76.
1991: Nguyen M; Bonneterre J; Hecquet B; Desoize B; Demaille A
Plasma acid and alkaline phosphatase in patients with breast cancer.
Anticancer research 1991;11(2):831-3.
1991: Fenaux-Allard I; Bonneterre J; Vilain M O; Fenaux P; Cabaret V; Delobelle-Deroide A; Demaille A
[Primary lymphomas of the breast. 9 case reports]
Journal de gynécologie, obstétrique et biologie de la reproduction 1991;20(2):163-7.
1991: Bonneterre J; Kerbrat P; Fargeot P; Metz R; Roche H; Bastit P; Chevrier A; Tubiana-Hulin M; Geyer G; Cappelaere P
Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(7):849-52.
1990: Peyrat J P; Bonneterre J; Vennin P H; Jammes H; Beuscart R; Hecquet B; Djiane J; Lefebvre J; Demaille A
Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumors.
The Journal of steroid biochemistry and molecular biology 1990;37(6):823-7.
1990: Bonneterre J; Peyrat J P; Beuscart R; Demaille A
Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer.
Cancer research 1990;50(21):6931-5.
1990: Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(6):1063-9.
1990: Bonneterre J
[Chemotherapy of cancer of the exocrine pancreas]
Bulletin du cancer 1990;77(3):267-74.
1989: Bonneterre J; Adenis L
[Nausea and vomiting induced by anticancer chemotherapy: mechanisms and prevention]
Pathologie-biologie 1989;37(2):163-4.
1989: Vennin P; Peyrat J P; Bonneterre J; Louchez M M; Harris A G; Demaille A
Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer.
Anticancer research 1989;9(1):153-5.
1989: Peyrat J P; Bonneterre J; Dusanter-Fourt I; Leroy-Martin B; Djiane J; Demaille A
Characterization of insulin-like growth factor 1 receptors (IGF1-R) in human breast cancer cell lines.
Bulletin du cancer 1989;76(3):311-9.
1988: Bonneterre J; Mauriac L; Weber B; Roche H; Fargeot P; Tubiana-Hulin M; Sevin M; Chollet P; Cappelaere P
Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial.
European journal of cancer & clinical oncology 1988;24(12):1851-3.
1988: Peyrat J P; Bonneterre J; Beuscart R; Djiane J; Demaille A
Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors.
Cancer research 1988;48(22):6429-33.
1988: Peyrat J P; Bonneterre J; Laurent J C; Louchez M M; Amrani S; Leroy-Martin B; Vilain M O; Delobelle A; Demaille A
Presence and characterization of insulin-like growth factor 1 receptors in human benign breast disease.
European journal of cancer & clinical oncology 1988;24(9):1425-31.
1987: Bonneterre J; Ghalim N; Nguyen M; Puchois P; Demaille A; Demarquilly C; Fruchart J C
Variations in lipoproteins during aminoglutethimide therapy.
Breast cancer research and treatment 1987;10(2):197-200.
1987: Bonneterre J; Pion J M; Demaille A
[Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast]
Bulletin du cancer 1987;74(3):241-7.
1986: Bonneterre J; Coppens H; Mauriac L; Rouesse J; Fargeot P; Metz R; Armand J P; Mathieu A; Tubiana M; Cappelaere P
[Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day]
Acta clinica Belgica. Supplementum 1986;11():41-8.
1985: Bonneterre J; Coppens H; Mauriac L; Metz M; Rouesse J; Armand J P; Fargeot P; Mathieu M; Tubiana M; Cappelaere P
Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.
European journal of cancer & clinical oncology 1985;21(10):1153-8.
1985: Bonneterre J; Horner D; Peyrat J P; Vandewalle B; Cambier L; Demaille A
Estradiol and progesterone receptors in breast cancer: prognostic value after relapse.
Breast cancer research and treatment 1985;5(2):149-54.
1984: Peyrat J P; Djiane J; Bonneterre J; Vandewalle B; Vennin P; Delobelle A; Depadt G; Lefebvre J
Stimulation of DNA synthesis by prolactin in human breast tumor explants. Relation to prolactin receptors.
Anticancer research 1984;4(4-5):257-61.
1983: Vandewalle B; Peyrat J P; Bonneterre J; Hecquet B; Dewailly D; Lefebvre J
Nuclear estradiol-binding sites in human breast cancer.
Cancer research 1983;43(9):4497-503.
1981: Peyrat J P; Dewailly D; Djiane J; Kelly P A; Vandewalle B; Bonneterre J; Lefebvre J
Total prolactin binding sites in human breast cancer biopsies.
Breast cancer research and treatment 1981;1(4):369-73.
1980: Dewailly D; Bonneterre J; Vandewalle B; Delobelle A; Lefebvre J; Demaille A C
[Determination of cytosolic receptors for estradiol and progesterone in 137 cases of breast cancer: technics, clinical and histopathological correlations]
Lille médical : journal de la Faculté de médecine et de pharmacie de l'Université de Lille 1980;25(9):496-501.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Jacques Bonneterre

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Jacques Bonneterre (preview)

All Publications